Salesforce
CRM
$240.70
-2.45%
Salesforce, Inc. is the world's leading enterprise cloud software company, providing Customer Relationship Management (CRM) technology through its Customer 360 platform, which unifies sales, service, marketing, commerce, and data integration (MuleSoft) capabilities for businesses across industries. The company is the dominant platform incumbent in the CRM software market, with a subscription-based model that generates highly recurring revenue and deep enterprise entrenchment, positioning it as a bellwether for enterprise software spending. The current investor narrative centers on Salesforce's aggressive capital return program — highlighted by Marc Benioff's roughly $25 billion buyback bet against the "SaaSpocalypse" — combined with its pivot to AI monetization through Agentforce and a landmark partnership with Anthropic that converts a perceived AI disruption threat into an upsell channel. Following a blowout Q2 FY2027 earnings report in late August 2026 that sent shares surging roughly 20% in a single session, the debate has shifted from existential AI risk to whether the stock's re-rating still leaves room for upside at roughly 15x forward earnings.…
CRM
Salesforce
$240.70
Related headlines
Investment Opinion: Should I buy CRM Today?
Rating: Buy (accumulate on weakness). The core thesis is that Salesforce is a high-margin, cash-generative software incumbent trading at a trough valuation of 15.0x forward earnings and 4.86x sales, with the AI disruption threat neutralized by the Anthropic partnership and a $27.2 billion buyback signaling management conviction. The analyst consensus of 'buy' (mean 1.70 across 54 analysts) with an average target of $285.68 implies +18.7% upside, anchoring the view.
Supporting evidence is strong across four dimensions: (1) valuation — 15.0x forward PE versus a historical trailing PE band that peaked at 47.99x in Q4 FY2025, and 4.86x PS versus 24.1x in Q2 FY2026; (2) profitability — 31.1% net margin in Q2 FY2027 versus 18.4% a year earlier, with 44.3% EBITDA margin; (3) cash generation — trailing FCF of $15.154 billion represents a ~7.5% FCF yield on the $201.7 billion market cap; and (4) growth — +10.83% YoY revenue with consensus of $71.5 billion implying continued low-double-digit expansion. The PEG ratio of 1.24 is reasonable for a business growing earnings at a high-teens clip.
Key risks that could invalidate the thesis: revenue growth decelerating below 10% as Microsoft and ServiceNow take share, AI monetization (Agentforce) failing to materialize, and the buyback constraining liquidity given the 0.76 current ratio. The rating would upgrade to a stronger Buy if forward PE stays below 15x while revenue growth reaccelerates above 12%, and would downgrade to Hold if growth falls below 8% or if the stock breaks below $225 support. Verdict: the stock is undervalued relative to its own history and fairly valued to modestly cheap versus mature software peers, with the discount reflecting legitimate growth concerns rather than structural deterioration.
Sign up to view all
CRM 12-Month Price Forecast
The forward-looking view is constructive but not without caveats: the valuation de-rating to 15.0x forward earnings and 4.86x sales is extreme relative to 76.7% gross margins and 44.3% EBITDA margins, and the margin inflection to 31.1% net margin is concrete evidence of operating leverage. The Anthropic partnership and Agentforce pivot remove the existential AI bear thesis, while the $27.2 billion buyback provides a floor under EPS. However, revenue growth of +10.83% is structurally decelerating, and the -17.68 point one-year relative strength gap versus SPY shows the recovery is recent and incomplete. I would upgrade to high confidence if Agentforce bookings show measurable acceleration in the next two quarters, and would downgrade to neutral if revenue growth falls below 9% or if the stock breaks below $225 support.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Salesforce's 12-month outlook, with a consensus price target around $285.68 and implied upside of +18.7% versus the current price.
Average Target
$285.68
0 analysts
Implied Upside
+18.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$165 - $475
Analyst target range
Coverage is deep and broadly constructive: 54 analysts cover Salesforce with a consensus recommendation of "buy" (mean rating of 1.70 on a 1-5 scale where 1 is strong buy), and the average target price of $285.68 implies +18.7% upside from the current $240.70. The consensus leans bullish, supported by a cluster of recent Buy/Outperform reiterations from Stifel, Guggenheim, BMO Capital, Canaccord Genuity, Citizens, and Freedom Broker in mid-September 2026, alongside Neutral/Equal Weight stances from Citigroup, Wells Fargo, RBC Capital, and Stephens & Co. — a split that reflects genuine debate about AI monetization timing and growth durability rather than broad skepticism. The distribution of ratings and the absence of any recent downgrades suggest the sell-side is holding its ground after the Q2 earnings beat, with the neutral camp likely anchored on valuation and competitive concerns rather than fundamental deterioration. The target range is extraordinarily wide — from a low of $165.00 (roughly -31.5% downside) to a high of $475.00 (roughly +97.3% upside) — a spread of $310 that signals high uncertainty and divergent assumptions among analysts. The high target of $475 likely assumes aggressive AI-driven reacceleration, multiple expansion back toward historical SaaS premiums, and successful Agentforce monetization at scale, while the low target of $165 prices in margin compression, competitive share loss to Microsoft and ServiceNow, and a return to the growth-scare valuation trough. The wide dispersion, combined with the stock's 1.256 beta and -43.61% maximum drawdown, argues for disciplined position sizing and a focus on the $285 average target as the base case, with the $225 technical support as a key risk-management level for anyone establishing or adding to a position.
Drowning in data?
Find the real signal!
Bulls vs Bears: CRM Investment Factors
The bull case currently has stronger evidence: the valuation de-rating to 15.0x forward earnings and 4.86x sales is extreme relative to 76.7% gross margins and 44.3% EBITDA margins, the margin inflection to 31.1% net margin is concrete, and the Anthropic partnership removes the existential AI bear thesis. However, the bear case is not without merit — revenue growth of +10.83% is structurally decelerating, and the stock's -17.68 point one-year relative strength gap versus SPY shows the recovery is recent and incomplete. The single most important tension is whether Agentforce and AI monetization can reaccelerate growth back toward mid-teens, or whether ~11% growth is the new ceiling that justifies a permanently lower multiple. If AI upsell proves real, the stock is materially undervalued; if growth stalls at 10%, the current 15x forward PE is fair rather than cheap.
Bullish
- Deep valuation de-rating creates margin of safety: CRM trades at just 15.0x forward earnings and 4.86x sales, versus historical PS ratios of 17.7x in Q4 FY2026 and 24.1x in Q2 FY2026. The trailing PE has compressed from 47.99x in Q4 FY2025 to 27.0x today, placing the stock near the bottom of its multi-year valuation band despite 76.7% gross margins and 20.5% operating margins.
- Margin expansion is real and accelerating: Q2 FY2027 net income of $3.526 billion represented a 31.1% net margin, up sharply from 18.4% in Q2 FY2026, while EBITDA reached $5.025 billion (44.3% margin). Gross margin has been stable in the 76.7%-78.0% band, meaning the profit inflection is driven by operating expense leverage rather than one-off items.
- Massive buyback signals management conviction: Salesforce repurchased $27.2 billion of stock in Q1 FY2027 alone, and Marc Benioff's roughly $25 billion buyback bet against the 'SaaSpocalypse' is now paying off as shares have surged +40.95% over three months. Share count has fallen from 974 million diluted in Q4 FY2025 to 821 million in Q2 FY2027, mechanically boosting EPS.
- AI threat converted into partnership opportunity: The landmark Anthropic partnership converts what was perceived as an existential AI disruption threat into an upsell channel through Agentforce, removing a major bear thesis. This reframes the AI narrative from 'Salesforce gets disintermediated' to 'Salesforce monetizes AI on top of its entrenched Customer 360 platform.'
Bearish
- Growth decelerated to low-double digits: Q2 FY2027 revenue of $11.345 billion grew only +10.83% year-over-year, a far cry from Salesforce's 20%+ historical growth and typical of a mature software incumbent. Consensus revenue of $71.5 billion implies continued low-double-digit expansion, limiting the case for multiple re-rating.
- Relative strength still lags the market badly: Despite the recent surge, CRM is down -2.15% over the past year versus SPY's +15.53%, a relative strength gap of -17.68 points, and is down -5.09% YTD versus SPY's +11.93%. The 1-month relative underperformance of -5.15 points versus SPY signals the post-earnings momentum is fading.
- Extreme analyst target dispersion: Targets range from $165 (-31.5% downside) to $475 (+97.3% upside), a $310 spread that signals high uncertainty about AI monetization timing and growth durability. The low target prices in margin compression and competitive share loss to Microsoft and ServiceNow.
- Liquidity and leverage nuance: The current ratio of 0.76 is below 1.0, reflecting large deferred revenue and buyback-driven cash usage, and Q2 operating cash flow of $1.269 billion was seasonally light after Q1's $6.701 billion. The aggressive $27.2 billion buyback leaves less cushion than the headline 0.29 debt-to-equity ratio suggests.
CRM Technical Analysis
Salesforce is in a recovery uptrend that has not yet fully repaired a difficult twelve-month stretch: the stock is down -2.15% over the past year versus a +15.53% gain for SPY, a relative strength gap of -17.68 percentage points. At $240.70, the stock sits at approximately 76.8% of its 52-week range (low $146.32, high $269.11), meaning it has reclaimed most of the ground lost during the mid-2026 drawdown but remains about 10.6% below its high — a positioning that reflects improving momentum without the overextension typical of a stock pressing all-time highs. The maximum drawdown of -43.61% over the trailing period underscores how violent the prior selloff was, and the current recovery should be viewed as a trend repair rather than a mature bull leg. Recent momentum is sharply bifurcated: the stock has gained +40.95% over three months and +32.15% over six months, dramatically outperforming SPY's +2.69% and +7.48% respectively (relative strength of +38.26 and +24.67 points), yet it has slipped -3.93% over the past month against SPY's +1.22%, a -5.15 point relative underperformance. This divergence signals a healthy post-earnings consolidation after the August breakout rather than a trend reversal — the 1-month pullback is shallow relative to the 3-month surge, and the stock has already rebounded from its late-September dip near $225 back to $240.70. Year-to-date the stock is still down -5.09% versus SPY's +11.93%, confirming that the recovery is recent and the longer-term trend remains unresolved. Key technical levels are well defined: support sits at the 52-week low of $146.32, with intermediate support around the $225-227 area that held during the late-September pullback, while resistance is the 52-week high of $269.11 — a breakout above that level would confirm a full trend reversal and likely trigger momentum-driven buying, whereas a breakdown below $225 would signal the August gap is failing and reopen the $190-200 zone. With a beta of 1.256, Salesforce is roughly 26% more volatile than the market, meaning position sizing should account for amplified drawdowns; the short ratio of 2.47 indicates moderate short interest that could add fuel to a breakout but is not extreme enough to suggest a crowded bear thesis.
Beta
1.26
1.26x market volatility
Max Drawdown
-43.6%
Largest decline past year
52-Week Range
$146-$269
Price range past year
Annual Return
-2.2%
Cumulative gain past year
| Period | CRM Return | S&P 500 |
|---|---|---|
| 1m | -3.9% | +0.2% |
| 3m | +40.9% | +2.9% |
| 6m | +32.2% | +8.4% |
| 1y | -2.2% | +14.9% |
| ytd | -5.1% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CRM Fundamental Analysis
Salesforce's revenue trajectory remains solidly growing but is decelerating to high-single-digit rates typical of a mature software incumbent: Q2 FY2027 revenue of $11.345 billion grew +10.83% year-over-year, building on a multi-quarter progression from $10.236 billion in Q2 FY2026 and $10.259 billion in Q3 FY2026, with sequential growth of roughly 1.9% quarter-over-quarter. The subscription and support segment dominates the mix at $10.82 billion versus just $525 million in professional services, meaning growth is driven almost entirely by the recurring core — a high-quality revenue base, though the ~11% growth rate is a far cry from the 20%+ growth of Salesforce's earlier years and explains why the market has debated the stock's multiple compression. The investment case therefore hinges less on top-line acceleration and more on AI monetization (Agentforce) and operating leverage, with consensus revenue estimates of $71.5 billion implying continued low-double-digit expansion. Profitability has inflected meaningfully: Q2 FY2027 net income reached $3.526 billion (a 31.1% net margin) on gross margin of 76.65%, with operating margin at 20.5% and EBITDA of $5.025 billion (44.3% EBITDA margin). The margin trajectory is clearly expanding — net margin has climbed from 18.4% in Q2 FY2026 to 31.1% in the latest quarter, and operating margin has risen from 22.8% to 20.5% on a GAAP basis while non-GAAP profitability benefits from cost discipline and restructuring. Gross margin has been remarkably stable in the 76.7%-78.0% band across recent quarters, consistent with premium SaaS economics, and the combination of stable gross margins with rising net margins points to operating expense leverage rather than pricing power as the profit driver. Balance sheet and cash flow metrics are healthy but warrant nuance: debt-to-equity is a conservative 0.29, ROE is 12.6%, and ROA is 5.7%, while trailing free cash flow of $15.154 billion represents a robust FCF yield of roughly 7.5% on the $201.7 billion market cap. However, the current ratio of 0.76 is below 1.0, reflecting the company's large deferred revenue and buyback-driven cash usage rather than distress, and Q2 operating cash flow of $1.269 billion was seasonally light (FCF of $1.098 billion) after a strong Q1 of $6.701 billion — the company also repurchased $27.2 billion of stock in Q1 FY2027, a massive capital return that constrains near-term liquidity but signals management's conviction in undervaluation. With $8.31 billion in cash at quarter-end and modest leverage, Salesforce funds growth internally and still returns capital, though the aggressive buyback leaves less cushion than the headline debt ratio suggests.
Quarterly Revenue
$11.3B
2026-07
Revenue YoY Growth
+10.8%
YoY Comparison
Gross Margin
76.6%
Latest Quarter
Free Cash Flow
$15.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CRM Overvalued?
Because Salesforce is solidly profitable (Q2 net income of $3.526 billion), the PE ratio is the appropriate primary metric: the stock trades at 27.0x trailing earnings but only 15.0x forward earnings, a dramatic 44% compression that implies the market expects substantial EPS growth — consistent with consensus FY estimates of $25.37, which would represent roughly 80% growth off the trailing base. The trailing PE of 27.0x is also well below the historical quarterly PE readings of 32.8x (Q2 FY2026), 41.7x (Q1 FY2026), and 47.99x (Q4 FY2025), reflecting both earnings growth and multiple contraction. On a price-to-sales basis, the stock trades at 4.86x versus historical PS ratios of 13.3x (Q2 FY2027 reported), 17.7x (Q4 FY2026), and 24.1x (Q2 FY2026) — a staggering de-rating that underscores how far sentiment has fallen from the 2021-2023 SaaS premium era. Peer comparison is constrained by the absence of an explicit industry-average multiple in the provided valuation data, but the stock's 4.86x PS and 5.33x EV/Sales are consistent with a mature, high-margin application software company rather than a hyper-growth SaaS name, and its 15.0x forward PE sits at a discount to the broader software group's typical 25-35x range — a discount that appears unjustified given 76.7% gross margins, 20.5% operating margins, and double-digit revenue growth. The PEG ratio of 1.24 is reasonable for a company growing earnings at a high-teens-to-20% clip, and the 16.1x EV/EBITDA is moderate for a business with 44% EBITDA margins. Historical context is the most compelling part of the valuation case: the stock's own PE band has compressed from 47.99x in Q4 FY2025 to 27.0x today, and its PS ratio has fallen from 32.8x in Q4 FY2025 to 4.86x — placing the stock near the bottom of its multi-year valuation range. This suggests the market is pricing in pessimistic expectations (AI disruption, growth deceleration) rather than optimistic ones, creating a potential value opportunity if AI monetization and margin expansion continue to deliver — though the risk is that the de-rating reflects genuine structural deterioration in the growth outlook rather than temporary sentiment.
PE
27.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~247x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the tension between aggressive capital return and liquidity. Salesforce repurchased $27.2 billion of stock in Q1 FY2027, leaving only $8.31 billion in cash at Q2 quarter-end and a current ratio of 0.76 — below 1.0 — which reflects large deferred revenue obligations and buyback-driven cash usage rather than distress, but leaves less cushion than the 0.29 debt-to-equity ratio implies. Q2 operating cash flow of $1.269 billion (FCF $1.098 billion) was seasonally light after Q1's $6.701 billion, so any cash flow miss would constrain the buyback that has been a key support for EPS. Revenue concentration in subscription and support ($10.82 billion of $11.345 billion) is high-quality but means growth depends almost entirely on the ~11% recurring core, and the deceleration from 20%+ historical growth to +10.83% YoY limits operating leverage upside if AI monetization disappoints.
Market and competitive risks are dominated by valuation compression and platform competition. Even after the de-rating to 15.0x forward earnings and 4.86x sales, the stock carries a 1.256 beta, meaning a 10% market decline could translate to roughly a 12.6% drawdown, and the -43.61% maximum drawdown over the trailing period shows how violent sentiment swings have been. Microsoft and ServiceNow are intensifying competition — recent coverage notes ServiceNow's expanding AI partnership with Aramco alongside Microsoft and Salesforce AI ambitions, warranting a cautious approach — and Veeva's raised FY27 outlook with strong Vault CRM adoption signals share pressure in life sciences. The wide analyst target range of $165 to $475 reflects genuine disagreement about whether AI is a tailwind or a threat, and any negative AI monetization datapoint could trigger multiple compression back toward the low end.
Worst-case scenario: AI monetization disappoints in the next two quarters, Agentforce bookings come in below expectations, and Microsoft/ServiceNow win marquee enterprise deals, causing analysts to cut targets toward the $165 low (-31.5% from $240.70). Combined with a market rotation out of software on rising rates, the stock could retest the $190-200 zone (a -17% to -21% move) and, in a severe scenario, approach the 52-week low of $146.32, a -39.2% decline from current levels. The $225-227 technical support is the first line of defense; a breakdown there would confirm the August gap is failing and materially raise the probability of the bear case.
FAQ
Ranked by severity: (1) Growth deceleration — revenue grew only +10.83% YoY in Q2 FY2027, and a fall below 8-9% would compress the multiple further; (2) Competitive pressure — Microsoft and ServiceNow are intensifying AI competition, and Veeva's raised FY27 outlook with strong Vault CRM adoption signals share pressure; (3) Liquidity and buyback risk — the current ratio of 0.76 and $27.2 billion Q1 buyback leave only $8.31 billion in cash, constraining flexibility if cash flow disappoints; (4) Valuation and volatility risk — a 1.256 beta and -43.61% max drawdown mean market rotations could amplify losses, with the $165 analyst low representing -31.5% downside.
The 12-month forecast has three scenarios: bull case (30% probability, $285-340) assumes Agentforce monetization accelerates growth toward 13-15% and multiple re-rates to 18-20x forward earnings; base case (50% probability, $265-290) assumes ~11% revenue growth, stable margins, and the stock grinding toward the $285.68 analyst average; bear case (20% probability, $165-200) assumes AI monetization disappoints, growth falls below 10%, and the stock breaks below $225 support. The base case is most likely, anchored on the analyst average target of $285.68 (+18.7% upside) and the assumption that revenue growth sustains at ~10-11% consistent with Q2 FY2027's +10.83%. The key assumption is that Agentforce and the Anthropic partnership generate measurable upsell without a major competitive share loss.
CRM appears undervalued relative to its own history: the trailing PE of 27.0x is well below the 47.99x reading in Q4 FY2025, and the PS ratio of 4.86x is a fraction of the 24.1x seen in Q2 FY2026. The forward PE of 15.0x sits at a discount to the broader software group's typical 25-35x range, which appears unjustified given 76.7% gross margins, 20.5% operating margins, and double-digit revenue growth. The PEG ratio of 1.24 is reasonable for a company growing earnings at a high-teens clip, and the 16.1x EV/EBITDA is moderate for a 44.3% EBITDA-margin business. The market is pricing in pessimistic expectations (AI disruption, growth deceleration) rather than optimistic ones, creating a potential value opportunity if AI monetization delivers.
From a risk/reward perspective, CRM offers an attractive setup: the stock trades at 15.0x forward earnings with an analyst average target of $285.68 implying +18.7% upside, and the consensus rating is 'buy' (1.70 mean across 54 analysts). The biggest downside risk is a break below $225 support that could reopen the $190-200 zone (-17% to -21%) or, in a severe scenario, the $165 analyst low (-31.5%). The margin of safety comes from the deep valuation de-rating — 4.86x sales versus 24.1x in Q2 FY2026 — and the 31.1% net margin. It is a good buy for value-oriented investors with a 12-18 month horizon who can tolerate a 1.256 beta and -43.61% historical max drawdown, particularly on pullbacks toward the $225-227 support. It is less suitable for short-term traders given the recent -3.93% one-month consolidation.
CRM is better suited for long-term holding (minimum 12-18 months) than short-term trading. The stock is in a recovery uptrend that has not fully repaired a difficult twelve-month stretch — down -2.15% over the past year versus SPY's +15.53% — and the -43.61% max drawdown with a 1.256 beta means short-term volatility is high. The dividend yield of 0.79% is modest, so total return depends on multiple re-rating and EPS growth from the buyback and margin expansion, which take time to play out. Earnings visibility is solid given the subscription model ($10.82 billion of $11.345 billion revenue is recurring), supporting a long-term thesis. A concrete suggested minimum holding period is 12-18 months to capture the base-case target of $265-290 and allow Agentforce monetization evidence to materialize.
